First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine

W R Bezwoda; R Dansey; L Seymour

doi:10.1159/000226717

First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine

Oncology. 1989;46(4):208-11. doi: 10.1159/000226717.

Authors

W R Bezwoda¹, R Dansey, L Seymour

Affiliation

¹ Department of Medicine, Haematology/Oncology, University of the Witwatersrand, Johannesburg, South Africa.

PMID: 2740063
DOI: 10.1159/000226717

Abstract

Seventy-five patients with stage 4 breast cancer were treated with a first-line chemotherapy regimen consisting of cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1.4 mg/m2 (CNV). Objective response was seen in 61/75 (81%) with 17/75 (23%) complete remission (CR). Median duration of response was 38 weeks overall and 51 weeks for patients achieving CR. CNV is an effective regimen for the treatment of advanced breast cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Cyclophosphamide / administration & dosage
Female
Hematologic Diseases / chemically induced
Humans
Male
Middle Aged
Mitoxantrone / administration & dosage
Vincristine / administration & dosage

Substances

Vincristine
Cyclophosphamide
Mitoxantrone